Table 2.

Clinical and molecular characteristics of 100 CRCs selected for CGH and the mean of copy number changes estimated by CGH using HME, IME, and LME CRC clusters

Clinical and molecular CharacteristicsTotal, n (%)aHME, n (%)aIME, n (%)LME, n (%)P (HME vs. IME)P (HME vs. LME)P (IME vs. LME)P (HME vs. IME vs. LME)
100 (100)20 (20)40 (40)40(40)
Age, mean ± SD65 ± 1167 ± 1365 ± 1065 ± 110.5170.6110.8680.775
Female48 (48)13 (65)18 (45)17 (42)0.1770.1701.0000.271
Male52 (52)7 (35)22 (55)23 (58)
Proximal28(28)15 (75)8 (20)5 (12)5.88 × 10−52.54 × 10−60.5462.95 × 10−6
Distal72 (72)5 (15)32 (80)35 (88)
BRAF mutant15 (15)14 (70)0 (0)1 (2)5.88 × 10−92.54 × 10−81.0002.95 × 10−11
BRAF wild-type85 (85)6(30)40 (100)39 (98)
KRAS mutant30 (30)2 (10)21 (52)11 (27)0.0030.1800.040.00461
KRAS wild-type70(70)18 (90)19 (48)29 (73)
MSI14 (14)11 (55)2 (5)1 (2)2.64 × 10−54.89 × 10−61.0003.22 × 10−7
MSS86 (86)9 (45)38 (95)39 (98)
CGH mean changes ± SD7.6 ± 6.54.5 ± 5.510.4 ± 6.96.25 ± 5.60.0010.1420.0040.001
CGH mean amplifications ± SD3.7 ± 3.61.9 ± 2.84.7 ± 3.73.4 ± 3.60.0010.0450.0640.003
CGH mean deletions ± SD3.9 ± 4.02.5 ± 3.65.7 ± 4.52.8 ± 3.00.0070.4180.0030.003
  • aData adapted from Kozlowska et al. (27).